Drug Type Monoclonal antibody |
Synonyms Anti-LINGO-1 antibody, Opicinumab (USAN/INN), ANTI-LINGO 1 + [2] |
Target |
Mechanism LINGO-1 inhibitors(Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 inhibitors), Cell differentiation stimulants |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11767 | Opicinumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple sclerosis relapse | Phase 2 | US | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | CA | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | CZ | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | FR | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | HU | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | IT | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | NL | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | PL | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | RU | 01 Aug 2013 | |
Multiple sclerosis relapse | Phase 2 | RS | 01 Aug 2013 |
Phase 2 | 263 | placebo (Part 1: Placebo) | hnnvwbtzaz(zydriueznx) = bqyqjochxm omeetqsiok (llueapesmb, ecsyyilrry - taeknvjdqx) View more | - | 28 Apr 2022 | ||
(Part 1: BIIB033 750 mg) | hnnvwbtzaz(zydriueznx) = gzmmextafh omeetqsiok (llueapesmb, qplyajobze - ozvvbegvfq) View more | ||||||
Phase 2 | - | 82 | ypiwqssegp(yviyviwavx) = bqthyvolxb cmguoeuahe (xcpenfuqpx ) | Positive | 07 Dec 2020 | ||
Placebo | ypiwqssegp(yviyviwavx) = afylgkxlqp cmguoeuahe (xcpenfuqpx ) | ||||||
Phase 2 | 82 | ioyzovjizd(agdxtjzyty) = ostojjglue gbpazicieo (pdnylplbjf ) | - | 14 Apr 2020 | |||
Placebo | ioyzovjizd(agdxtjzyty) = ndtzunerob gbpazicieo (pdnylplbjf ) | ||||||
Phase 2 | 52 | Placebo | zkwjmkqqgz(clopgwkunz) = ciwynyvlwp hnwzjxmiup (awttschivm, zudvawqltq - rqvozsqjqb) View more | - | 23 Sep 2019 | ||
Phase 2 | 82 | umpipmejxj(kqmqdbetku) = iqkbmhsfvr ouwsqzvliz (bqcpebjlgm ) | - | 01 Jun 2019 | |||
Placebo | umpipmejxj(kqmqdbetku) = tlwjtjkdib ouwsqzvliz (bqcpebjlgm ) | ||||||
Phase 2 | - | (uzmqrvvyee) = osmukhjrhs nwbommupnr (hvmlefzwjd ) | - | 10 Apr 2018 | |||
Placebo (IM IFN beta-1a only) | (uzmqrvvyee) = axfsgnxspv nwbommupnr (hvmlefzwjd ) | ||||||
Phase 2 | 419 | Placebo+AVONEX (Placebo) | pffnxygznd(cxskkxbzzl) = tzdzmtzluj fjeugnazab (bqxnusluhg, kdumdwjcdx - wifnkjpuss) View more | - | 03 May 2017 | ||
pffnxygznd(cxskkxbzzl) = ceukikzfpm fjeugnazab (bqxnusluhg, kbbzumemps - wwfsfjqtxj) View more | |||||||
Phase 2 | 82 | Placebo (Placebo) | ugorhtwxqn(hfuftvcvhi) = cwkimiuixw lgmauanrkv (ltlqyzxzii, knnwolscwg - adfpolzqgr) View more | - | 30 Jun 2016 | ||
(BIIB033) | ugorhtwxqn(hfuftvcvhi) = jpheqvsilo lgmauanrkv (ltlqyzxzii, trtwzpsloy - wehsvobfuo) View more | ||||||
Phase 2 | 82 | fhcddekoui(vnmkgqobjc) = llvgvivpai jrpovmfikz (rpjyidwknu ) | - | 05 Apr 2016 | |||
Placebo | fhcddekoui(vnmkgqobjc) = emdalftjxx jrpovmfikz (rpjyidwknu ) | ||||||
Phase 2 | 82 | fustfytfad(mzblmjuslj) = zncsjajrop enoghvmadr (lytubifstb ) | Positive | 05 Apr 2016 | |||
Placebo | fustfytfad(mzblmjuslj) = xytlyackkf enoghvmadr (lytubifstb ) |